[Retracted] Upregulating hsa-miR-128a Increased the Effects of Pembrolizumab on Laryngeal Cancer Cells via the p53 Pathway

Figure 3

BMI-1 is a target of hsa-miR-128a confirmed by dual luciferase assays. (a) Sequences were compared between mature hsa-miR-128a and the wild-type (WT) and mutant (MUT) target sites in the 3 UTR of BMI-1. (b) Cells were cotransfected with pMIR-REPORT containing the empty control, wild-type, or mutant target site of the BMI-1 3 UTR plus hsa-miR-128a or negative control mimic for 48 hours. The luciferase activities were normalized to Renilla luciferase activity and presented as relative activities to the corresponding negative control. Values were calculated from three independent assays ().

(a)

(b)